For decades, a science-first mindset has guided the life sciences industry. The strongest molecules and boldest ideas propelled companies to the top. But as biopharma enters a turbulent decade, scientific innovation alone is no longer enough.
Innovation in the lab remains essential. However, CRB’s latest Horizons: Life Sciences report – drawing on insights from more than 400 biopharma executives worldwide – suggests that future leaders will be distinguished by how effectively they deliver what they discover. Operational execution is moving to the center of competitive strategy.
The price imperative
While speed was key for a time, with R&D costs at historic highs, regulatory timelines in flux, and competition accelerating worldwide, enduring commercial value is fast becoming the measure of success. That shift is visible in how companies are investing. Two-thirds of large firms surveyed in CRB’s report are pursuing continuous manufacturing or process intensification. For many, it’s the logical next step in an era when batch-based paradigms can’t keep pace with commercial realities.
Continuous manufacturing has moved beyond addressing supply shortages; it is becoming a strategic capability. The model offers higher yields, reduced waste, smaller facility footprints, and improved productivity – alongside sustainability gains. For large firms with legacy stainless-steel networks, adoption requires a costly, multi-year transformation. Even so, momentum is building.
The FDA, too, appears ready to meet the moment. Drawing from its experience with continuous small-molecule plants, the agency has signaled support for innovation that enhances productivity and reliability. The challenge is not regulatory acceptance, but the industry’s willingness to be first. It’s less about what you discover and more about how fast, reliably, and cost-effectively you can deliver it to patients. The pioneers who embrace this truth, both technically and culturally, will define the next era of medicine.
Reshoring, reframing, and rebuilding
If value is the new measure of success, geography is the new strategy. One of the most striking findings from the Horizons report is that half of large biopharma firms are accelerating US manufacturing investments, despite tariff headwinds and regulatory turbulence.
At first glance, that may appear to be a reshoring wave. In practice, it’s more nuanced. Many of these projects were already planned, particularly in fast-growing markets such as GLP-1 therapies, therapeutic proteins, and antibody-drug conjugates (ADCs). What has changed is the framing.
In a geopolitical environment where domestic investment earns goodwill and tariff relief, companies are rebranding planned expansions as national commitments. It’s a smart strategy, but also underscores a larger truth: new facilities are no longer reactive, single-purpose builds. They’re strategic infrastructure.
That shift in mindset is driving a corresponding transformation in facility design.
The rise of the flexible facility
The historic model of biomanufacturing, which involves single-product facilities optimized for a single process over decades, is rapidly fading. In its place, companies are building modular, multi-product environments designed to pivot as pipelines evolve.
It’s not hard to see why. Betting hundreds of millions on a product that may fail in Phase III is no longer viable. The next generation of facilities must strike a balance between specialization and adaptability, enabling companies to adjust their production capacity and modality without tearing down and starting over.
That means “ballroom” layouts, flexible process utilities, modular cleanroom construction, and advanced automation architectures that can be reconfigured without significant downtime. These designs also accelerate delivery. Progressive design-build and target-value delivery models align engineering, construction, and operations teams around cost and flexibility goals from day one.
Speed-to-market reigned supreme in the early pandemic years; today, the pendulum has swung toward cost control. According to Horizons, 47 percent of companies now rank capital cost as their top project driver, compared to only 11 percent who prioritize schedule. Yet even in a cost-conscious climate, modularity and standardization are proving that flexibility doesn’t have to mean inefficiency. The best-performing projects deliver both agility and affordability.
Digitalization: promise meets pragmatism
As the industry rethinks its physical infrastructure, it is also grappling with digital. Few topics inspire as much debate as digital twins and data-driven operations. The vision of complete virtual replicas of facilities that can predict performance, optimize operations, and streamline commissioning is compelling.
Yet full-scale adoption remains limited. The technology is ready, but companies often aren't. The issue is less about capability and more about capacity: who maintains the model, interprets the data, and acts on it?
Most companies are taking a pragmatic approach. They’re laying the groundwork for digital twins by building data capture and automation into new projects without fully realizing them yet. It’s evolution, not revolution. But the trajectory is clear: future facilities will be digitally native by design.
The human equation
Yet even as technology advances, it’s people who will determine the industry’s success or failure. The Horizons report highlights an emerging challenge: a difficulty in staffing R&D, manufacturing, and engineering talent.
This talent gap comes at a moment when FDA restructuring and staff turnover have lengthened review timelines, creating new pressures on pipeline realization. In response, many companies are strengthening in-house regulatory and quality capabilities, recognizing that operational resilience depends as much on human expertise as on physical infrastructure.
That focus extends beyond compliance. It encompasses workforce wellbeing and engagement. The people producing these therapies understand, often literally, that lives depend on what they make. Designing workspaces that reflect human purpose, with well-lit, ergonomic, and collaborative environments, matters deeply. It improves safety, retention, and ultimately, quality. In a decade defined by automation, human empathy will remain a critical differentiator.
The decade ahead
Biopharma’s future will be defined by those who treat operational reinvention with the same urgency as scientific discovery. Continuous manufacturing, digital integration, and flexible facility design are existential capabilities. They are how innovation scales, how therapies reach patients faster, and how companies survive volatility.
The coming years will test which organizations can translate vision into velocity. The companies that thrive in the 2030s will not just invent the next breakthrough; they’ll reinvent themselves to deliver it.
Beyond acting as technical editor for the Horizons Life Sciences report, Peter Walters is a Fellow at CRB, with over 20 years of experience specializing in pharmaceutical process and facility design. He has a deep technical background in designing processes, equipment and spaces for multiprocess facilities predicated on maximum flexibility, logistics optimization, and technologies that reduce costs while allowing pipeline expandability and higher-quality therapeutics.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
